Teclistamab 153mg/1.7ml solution for injection vials
NHS hospitals in England used £20,086,958 of indicative cost of Teclistamab 153mg/1.7ml solution for injection vials in the 12 months to April 2026, about 0.1% of all hospital medicines spend. That is up 184.2% on the previous 12 months.
Indicative cost · 12 months
Quantity (VMP units) · 12 months
Share of hospital medicines spend
Figure 1. Teclistamab 153mg/1.7ml solution for injection vials: NHS hospital indicative cost by month (£ millions)
Source: NHSBSA Secondary Care Medicines Data, to April 2026
Cost is indicative — actual hospital medicine prices are commercially confidential, so these figures are estimated from list prices. See methodology.
NHS trusts using Teclistamab 153mg/1.7ml solution for injection vials most
By indicative cost over the 12 months to April 2026.
| NHS trust | Indicative cost (12 months) |
|---|---|
| University College London Foundation Tr | £2,861,813 |
| The Royal Marsden Nhs Foundation Trust | £1,715,507 |
| The Clatterbridge Cancer Centre Nhs Ft | £1,395,331 |
| Blackpool Teaching Hosp Nhs Found Trust | £1,253,031 |
| Univ Hpl B/Ham Nhs Foundation Trust | £1,138,401 |
| Somerset P/Ship Nhs Foundation Trust | £857,753 |
| Shrewsbury & Telford Hospital Nhs Trust | £837,989 |
| Gloucestershire Hpls Nhs Foundation Trst | £829,386 |
| Guy's & St Thomas' Nhs Foundation Trust | £814,273 |
| London North West Healthcare Nhs Trust | £759,236 |
The primary-care picture
No confident match to a community-dispensed medicine was found for this product, so no primary-care comparison is shown. SCMD products are recorded at product level, which does not always map cleanly to a BNF substance.